Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-2536. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 15/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | TAF1 | P21675 | 5/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-2536 SCHEMBL29395966 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL372489 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL16984416 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL29644993 | 0.99 | BRD4 (0.99) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL13227794 | 0.96 | BRD4 (0.92) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL24851804 | 0.96 | PLK1 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL4515444 | 0.95 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972068 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972069 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL376236 | 0.94 | PLK1 (0.89) | BRD4PLK1PLK3ALKTAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369214-A1 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | EMORY UNIVERSITY | 2018-12-27 | — | — | US | claimed |
| US-20080300206-A1 | Alpha-Synuclein Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12186311-B2 | Antiproliferative compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-115607552-B | Combination use of substituted 4-aminoisoindoline-1, 3-dione compounds and a second active agent | 新基公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300206-A1 | Alpha-Synuclein Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | PLK1 383/4885BRD4 715/4885PLK3 791/4885 |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | PLK1 2487/4885BRD4 1401/4885PLK3 2710/4885 |
| US-20080300206-A1 | Alpha-Synuclein Kinase | SNCA, PLK2, LMTK2 | PLK1 24/4885BRD4 1493/4885PLK3 6/4885 |
| US-12186311-B2 | Antiproliferative compounds and second active agents for combined use | NEK4, AURKB, XPO1 | PLK1 17/4885BRD4 11/4885PLK3 396/4885 |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | PLK1 107/4885BRD4 1458/4885PLK3 435/4885 |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885BRD4 1099/4885PLK3 359/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | PLK1 1607/4885BRD4 1105/4885PLK3 2100/4885 |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | PLK1 17/4885BRD4 11/4885PLK3 396/4885 |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | PLK1 4652/4885BRD4 436/4885PLK3 3723/4885 |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | CDK1, CDK4, CDK3 | PLK1 67/4885BRD4 217/4885PLK3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.